BCR and myeloid sarcoma: We chose to focus on miR-132 as it was most strongly implicated in the screen and using the same PCR platform confirmed in a total cohort of 14 MS patients and 13 HS, that miR-132 expression was abnormally increased in ‘dual BCR+CD40 activated’ MS B cells (Figure 1B; p = 0.0143).